| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PLRX | Common Stock | Award | $0 | +19.4K | +27.41% | $0.00 | 90.1K | Dec 19, 2022 | Direct | F1, F2 |
| transaction | PLRX | Common Stock | Sale | -$184K | -9.64K | -10.71% | $19.10 | 80.4K | Dec 20, 2022 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | On July 28, 2022, the Reporting Person was granted 77,500 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On December 19, 2022, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 19,375 shares. |
| F2 | Includes 3,071 shares of Common Stock acquired by the Reporting Person pursuant to an employee stock purchase program. |
| F3 | The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker at prices ranging from $18.4049 to $19.64, inclusive, on December 20, 2022 and December 21, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (3) to this Form 4. |